Clinical studies in pulmonary hypertension (PH) have historically focused primarily on Group 1 disease and, more specifically, on idiopathic PAH. However, there are many subtypes of PH within Group 1 and other pulmonary hypertension classes of which the physician must be aware. Awareness can lead to screening, earlier detection, and expedient referral from the community level to the PH specialty center. This program looks at forms of PH not routinely discussed, including PAH associated with systemic sclerosis and connective tissue disease, PAH associated with congenital heart disease, PH associated with interstitial lung disease, and finally, drug- and toxin-induced PH. The program focuses on screening, referral diagnosis, and management of the disease.
ReachMD
Be part of the knowledge.™We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Addressing PH Subtypes: Raising Awareness of Understudied Populations
Addressing PH Subtypes: Raising Awareness of Understudied Populations
How up to date are you on less common forms of pulmonary hypertension (PH)? Can you recognize adult congenital heart disease-associated PAH or scleroderma spectrum disorder-associated PAH? This program looks at understudied PH populations through the lenses of screening and diagnosis with an eye toward expedient referral to PH specialty centers. That next understudied PH patient might be the next one through your office door!
Overview
Target Audience
This activity has been designed to meet the educational needs of physicians, registered nurses, pharmacists and other healthcare professionals involved in the care of patients with pulmonary hypertension.
Learning Objectives
- Review characteristics of PH patient groups that fall outside of the idiopathic category
- Discuss the screening, diagnosis, and expedient referral of non-idiopathic patients to PH specialty centers from community generalists and specialty healthcare providers
- Focus on understudied PH groups that require special diagnostic attention by all healthcare providers
- Review treatment and management approaches to understudied PH patients
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.Faculty Disclosure of Commercial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
The following faculty has reported relationships with ineligible companies:
Richard Krasuski, MD, faculty for this educational event, receives research funds from Actelion/Janssen, Edwards Lifesciences, Corvia, CryoLife and Medtronic; and receives consulting fees from Actelion/Janssen and Gore Medical.
All the relevant financial relationships for these individuals have been mitigated.
Planners and Managers Disclosure List
The following reviewers/planners have reported no relationships with ineligible companies:
Dixon W. Wilde, PhD., FAHA, planner for this educational event, has no relevant financial relationships with ineligible companies.
Chad McQueen, PharmD, planner for this educational event, has no relevant financial relationships with ineligible companies.
William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.
All the relevant financial relationships for these individuals have been mitigated.
Provider(s)/Educational Partner(s)
Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.
Commercial Support
This activity is supported by educational grants from Actelion Pharmaceuticals US, Division of Janssen Pharmaceuticals and United Therapeutics Corporation.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Overview
Clinical studies in pulmonary hypertension (PH) have historically focused primarily on Group 1 disease and, more specifically, on idiopathic PAH. However, there are many subtypes of PH within Group 1 and other pulmonary hypertension classes of which the physician must be aware. Awareness can lead to screening, earlier detection, and expedient referral from the community level to the PH specialty center. This program looks at forms of PH not routinely discussed, including PAH associated with systemic sclerosis and connective tissue disease, PAH associated with congenital heart disease, PH associated with interstitial lung disease, and finally, drug- and toxin-induced PH. The program focuses on screening, referral diagnosis, and management of the disease.
Target Audience
This activity has been designed to meet the educational needs of physicians, registered nurses, pharmacists and other healthcare professionals involved in the care of patients with pulmonary hypertension.
Learning Objectives
- Review characteristics of PH patient groups that fall outside of the idiopathic category
- Discuss the screening, diagnosis, and expedient referral of non-idiopathic patients to PH specialty centers from community generalists and specialty healthcare providers
- Focus on understudied PH groups that require special diagnostic attention by all healthcare providers
- Review treatment and management approaches to understudied PH patients
Accreditation and Credit Designation Statements
In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.Faculty Disclosure of Commercial Relationships
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
The following faculty has reported relationships with ineligible companies:
Richard Krasuski, MD, faculty for this educational event, receives research funds from Actelion/Janssen, Edwards Lifesciences, Corvia, CryoLife and Medtronic; and receives consulting fees from Actelion/Janssen and Gore Medical.
All the relevant financial relationships for these individuals have been mitigated.
Planners and Managers Disclosure List
The following reviewers/planners have reported no relationships with ineligible companies:
Dixon W. Wilde, PhD., FAHA, planner for this educational event, has no relevant financial relationships with ineligible companies.
Chad McQueen, PharmD, planner for this educational event, has no relevant financial relationships with ineligible companies.
William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.
All the relevant financial relationships for these individuals have been mitigated.
Provider(s)/Educational Partner(s)
Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.
Commercial Support
This activity is supported by educational grants from Actelion Pharmaceuticals US, Division of Janssen Pharmaceuticals and United Therapeutics Corporation.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Facebook Comments